Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

New Line of Single-Use Bags Meets Stringent Requirements of the Biopharmaceutical Industry

By BiotechDaily International staff writers
Posted on 19 Jun 2014
Image: Flexsafe represents a completely new generation of single-use bags that offer consistent cell growth as well as extraordinary robustness and flexibility (Photo courtesy of Sartorius Stedim Biotech).
Image: Flexsafe represents a completely new generation of single-use bags that offer consistent cell growth as well as extraordinary robustness and flexibility (Photo courtesy of Sartorius Stedim Biotech).
A major global supplier of laboratory products for the biopharmaceutical industry has begun marketing a new range of single-use bags in a multitude of sizes and shapes.

Sartorius Stedim Biotech (Goettingen, Germany) has announced the release of its line of Flexsafe single-use bags. Flexsafe, which is based on S80, a multilayer, proprietary polyethylene (PE) film, was developed in close collaboration with resin and film suppliers. The PE film is 400 micrometers thick, making Flexsafe one of the strongest and most flexible bags currently on the market.

Optimization of resin formulation, complete control of raw materials quality, the extrusion process, and bag assembly guarantee lot-to-lot consistent cell growth performance of even the most sensitive cell lines.

Flexsafe bags are safe and easy to manage, even for the most demanding applications such as liquid shipping and large-scale stirred bioreactors. Batch-to-batch consistent extractables and leachables profiles, which support drug manufacture throughout all processes from clinical development to commercial supply, guarantee that initial extractable and leachable qualification data will remain valid for every operation involving single-use Flexsafe bioprocess products.

"Flexsafe represents a completely new generation of single-use bags," said Stefan Schlack, senior vice president marketing and product management at Sartorius Stedim Biotech. "They offer our customers consistent cell growth as well as extraordinary robustness and flexibility. In addition a sustainable supply chain and consistent film throughout the entire manufacturing process is guaranteed. Every single one of these benefits sets a new benchmark. Being unique in all of them makes us very proud.”

Initially Sartorius Stedim Biotech is launching Flexsafe RM bags (1–200 liters) and small bags for validation purposes. Bags for single use bioreactors BIOSTAT STR (50–2,000 liters) and additional applications such as storage, mixing, shipping, freezing and thawing will be introduced over the coming months.

Related Links:

Sartorius Stedim Biotech 



Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.